Scilex reports publication on Gloperba dosing adjustments

Scilex (SCLX) Holding Company, a company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced a publication on GLOPERBA dosing adjustments in peer-review journal. GLOPERBA is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, allowing for precision dosing and reduction of daily dose in patients with severe renal impairment. Analysis of pharmacokinetic model data demonstrated that most patients with renal impairment taking colchicine solid dosage formulations will be below or above therapeutic levels, exposing them to potential side effects. However, more precise dosing with colchicine oral solution of 0.48 mg for moderate renal impairment and 0.3 mg for severe renal impairment is associated with optimal levels within therapeutic widow and greater safety. “This important publication will provide much needed data to guide clinical dosing of colchicine in patients with gout and chronic renal failure.” – said Michael H. Pillinger, MD, Professor of Medicine and Biochemistry and Molecular Pharmacology, Director of Rheumatology Training, NYU Clinical and Translational Science Institute.